Last 12 months
Inside the activity.
3 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 2 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 18, 2026 Filed Aug 19, 2026 20:21 UTC |
Messinger MichaelChief Financial Officer
|
PurchaseCommon Stock, par value $0.0001 | 750 | $3.27 | $2,452.50 |
DisclosureSEC source: 0001437749-26-028540 · rdgdoc.xml · nonDerivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:04 UTC |
Baird Jennifer ADirector
|
GrantCommon Stock, par value $0.0001 | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022559 · rdgdoc.xml · nonDerivative · entry 1 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,620 F1 · shares: Represent a restricted stock unit award ("RSU"). The RSUs will vest in full on July 1, 2027. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:09 UTC |
Vincent Bernadette NDirector
|
GrantCommon Stock, par value $0.0001 | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022567 · rdgdoc.xml · nonDerivative · entry 1 Vincent Bernadette N · CIK 0002047074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,200 F1 · shares: Represent a restricted stock unit award ("RSU"). The RSUs will vest in full on July 1, 2027. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:08 UTC |
Neuman JohnDirector
|
GrantCommon Stock, par value $0.0001 | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022566 · rdgdoc.xml · nonDerivative · entry 1 Neuman John · CIK 0002026279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,200 F1 · shares: Represent a restricted stock unit award ("RSU"). The RSUs will vest in full on July 1, 2027. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:11 UTC |
Schlorff EricChief Executive Officer
|
GrantCommon Stock, par value $0.0001 | 10,288 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022573 · rdgdoc.xml · nonDerivative · entry 1 Schlorff Eric · CIK 0001949738 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,140 F1 · shares: Represents a restricted stock unit award ("RSU"). The RSU will vest in three equal installment on July 1, 2026, November 1, 2026, and March 1, 2027. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:10 UTC |
Chung KevinChief Medical Officer
|
GrantCommon Stock, par value $0.0001 | 7,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022569 · rdgdoc.xml · nonDerivative · entry 1 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,021 F1 · shares: Represents a restricted stock unit award ("RSU"). The RSU will vest in three equal installment on July 1, 2026, November 1, 2026, and March 1, 2027. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 21:08 UTC |
Van Heel KennethDirector
|
GrantCommon Stock, par value $0.0001 | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-022565 · rdgdoc.xml · nonDerivative · entry 1 Van Heel Kenneth · CIK 0001613111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,940 F1 · shares: Represent a restricted stock unit award ("RSU"). The RSUs will vest in full on July 1, 2027. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:57 UTC |
Baird Jennifer ADirector
|
GrantCommon Stock, par value $0.0001 | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003671 · rdgdoc.xml · nonDerivative · entry 1 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,620 F1 · shares: Represents a RSU award. The RSUs will vest in full on February 6, 2027. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:57 UTC |
Vincent Bernadette NDirector
|
GrantCommon Stock, par value $0.0001 | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003672 · rdgdoc.xml · nonDerivative · entry 1 Vincent Bernadette N · CIK 0002047074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,200 F1 · shares: Represents a RSU award. The RSUs will vest in full on February 6, 2027. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:58 UTC |
Neuman JohnDirector
|
GrantCommon Stock, par value $0.0001 | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003673 · rdgdoc.xml · nonDerivative · entry 1 Neuman John · CIK 0002026279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,200 F1 · shares: Represents a RSU award. The RSUs will vest in full on February 6, 2027. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:54 UTC |
Schlorff EricChief Executive Officer
|
GrantCommon Stock, par value $0.0001 | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003668 · rdgdoc.xml · nonDerivative · entry 1 Schlorff Eric · CIK 0001949738 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,852 F1 · shares: Represents an RSU award. The RSU award vests in equal installments on the first, second and third anniversaries of February 6, 2026 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:58 UTC |
Van Heel KennethDirector
|
GrantCommon Stock, par value $0.0001 | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003674 · rdgdoc.xml · nonDerivative · entry 1 Van Heel Kenneth · CIK 0001613111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,940 F1 · shares: Represents a RSU award. The RSUs will vest in full on February 6, 2027. Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:55 UTC |
Chung KevinChief Medical Officer
|
GrantCommon Stock, par value $0.0001 | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003669 · rdgdoc.xml · nonDerivative · entry 1 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,819 F1 · shares: Represents an RSU award. The RSU award vests in equal installments on the first, second and third anniversaries of February 6, 2026 Read SEC document |
| February 06, 2026 Filed Feb 10, 2026 21:56 UTC |
Towne Bradford KPrincipal Accounting Officer
|
GrantCommon Stock, par value $0.0001 | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-003670 · rdgdoc.xml · nonDerivative · entry 1 Towne Bradford K · CIK 0001728197 · Principal Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,050 F1 · shares: Represents an RSU award. The RSU award vests in equal installments on the first, second and third anniversaries of February 6, 2026 Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 23:55 UTC |
Baird Jennifer ADirector
|
PurchaseCommon Stock | 4,200 | $0.24 | $987.42 |
DisclosureSEC source: 0001437749-25-038577 · rdgdoc.xml · nonDerivative · entry 1 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,200 Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:49 UTC |
Messinger MichaelChief Financial Officer
|
PurchaseCommon Stock | 14,500 | $0.35 | $5,098.20 |
DisclosureSEC source: 0001437749-25-037589 · rdgdoc.xml · nonDerivative · entry 1 Messinger Michael · CIK 0001615039 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Read SEC document |
| August 27, 2025 Filed Aug 28, 2025 21:28 UTC |
Van Heel KennethDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $0.86 | $8,565.00 |
DisclosureSEC source: 0001214659-25-013006 · marketforms-70411.xml · nonDerivative · entry 2 Van Heel Kenneth · CIK 0001613111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,400 F2 · price: The price reported in Row 2, Column 4 is a weighted average price of $0.8565. These shares were purchased in multiple transactions at prices ranging from $0.8531 to $0.8599 inclusive. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 21:28 UTC |
Van Heel KennethDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 25,000 | $0.89 | $22,247.50 |
DisclosureSEC source: 0001214659-25-013006 · marketforms-70411.xml · nonDerivative · entry 1 Van Heel Kenneth · CIK 0001613111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,400 F1 · price: The price reported in Row 1, Column 4 is a weighted average price of $0.8899. These shares were purchased in multiple transactions at prices ranging from $0.885 to $0.89 inclusive. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 22, 2025 Filed Aug 25, 2025 22:21 UTC |
Chung KevinChief Medical Officer
|
PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $0.80 | $8,000.00 |
DisclosureSEC source: 0001213900-25-080440 · marketforms-70394.xml · nonDerivative · entry 1 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,184 Read SEC document |
| July 10, 2025 Filed Jul 16, 2025 23:47 UTC |
Baird Jennifer ADirector
|
GrantCommon Stock, par value $0.0001 per share | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064806 · marketforms-70097.xml · nonDerivative · entry 1 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Represents a restricted stock unit ("RSU") award. The RSUs will vest in full on July 3, 2026. Read SEC document |
| July 10, 2025 Filed Jul 16, 2025 23:45 UTC |
Vincent Bernadette NDirector
|
GrantCommon Stock, par value $0.0001 per share | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064804 · marketforms-70102.xml · nonDerivative · entry 2 Vincent Bernadette N · CIK 0002047074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 F4 · shares: Represents a RSU award. The RSUs will vest in full on July 3, 2026. F3 · balance_after: The total includes 5,333 shares underlying RSUs that were previously reported in Table II. Read SEC document |
| July 10, 2025 Filed Jul 16, 2025 23:45 UTC |
Neuman JohnDirector
|
GrantCommon Stock, par value $0.0001 per share | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064805 · marketforms-70099.xml · nonDerivative · entry 2 Neuman John · CIK 0002026279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 F4 · shares: Represents a RSU award. The RSUs will vest in full on July 3, 2026. F3 · balance_after: The total includes 5,333 shares underlying RSUs that were previously reported in Table II. Read SEC document |
| July 10, 2025 Filed Jul 16, 2025 23:45 UTC |
Van Heel KennethDirector
|
GrantCommon Stock, par value $0.0001 per share | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064802 · marketforms-70100.xml · nonDerivative · entry 2 Van Heel Kenneth · CIK 0001613111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,400 F4 · shares: Represents a RSU award. The RSUs will vest in full on July 3, 2026. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:33 UTC |
Schlorff EricDirector · Chief Executive Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 21,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061521 · marketforms-70035.xml · derivative · entry 2 Schlorff Eric · CIK 0001949738 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 21,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F6 · derivative.exercise_date: As previously reported, on November 15, 2024, the reporting person was granted 65,000 RSUs, vesting in three approximately equal annual installments on the first, second and third anniversaries of July 1, 2024. F6 · derivative.expiration_date: As previously reported, on November 15, 2024, the reporting person was granted 65,000 RSUs, vesting in three approximately equal annual installments on the first, second and third anniversaries of July 1, 2024. F7 · balance_after: The total does not include 43,333 shares underlying RSUs that are now reported in Table I. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:33 UTC |
Schlorff EricDirector · Chief Executive Officer
|
Exercise / conversionCommon Stock, par value $0.0001 per share | 21,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061521 · marketforms-70035.xml · nonDerivative · entry 1 Schlorff Eric · CIK 0001949738 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 is being filed to report the vesting of certain restricted stock unit ("RSU") awards and the moving of unvested RSU awards previously reported in Table II to Table I. F2 · shares: Reflects RSUs that upon vesting converted into shares of ICU common stock. F3 · balance_after: The total includes 43,333 shares underlying RSUs that were previously reported in Table II. F4 · balance_after: On June 7, 2024, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:33 UTC |
Chung KevinChief Medical Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061522 · marketforms-70034.xml · derivative · entry 2 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F6 · derivative.exercise_date: As previously reported, on November 15, 2024, the reporting person was granted 15,000 RSUs, vesting in three equal annual installments on the first, second and third anniversaries of July 1, 2024. F6 · derivative.expiration_date: As previously reported, on November 15, 2024, the reporting person was granted 15,000 RSUs, vesting in three equal annual installments on the first, second and third anniversaries of July 1, 2024. F7 · balance_after: The total does not include 25,000 shares underlying RSUs that are now reported in Table I. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 20:33 UTC |
Chung KevinChief Medical Officer
|
Exercise / conversionCommon Stock, par value $0.0001 per share | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061522 · marketforms-70034.xml · nonDerivative · entry 1 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,184 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 is being filed to report the vesting of certain restricted stock unit ("RSU") awards and the moving of unvested RSU awards previously reported in Table II to Table I. F2 · shares: Reflects RSUs that upon vesting converted into shares of ICU common stock. F3 · balance_after: The total includes 25,000 shares underlying RSUs that were previously reported in Table II. F4 · balance_after: Reflects a reduction by one share to correct a previous rounding error. Read SEC document |
| June 30, 2025 Filed Jul 2, 2025 23:32 UTC |
Baird Jennifer ADirector
|
PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $0.42 | $4,174.00 |
DisclosureSEC source: 0001213900-25-061153 · marketforms-70005.xml · nonDerivative · entry 2 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 F3 · balance_after: The total includes 5,333 shares underlying RSUs that were previously reported in Table II. Read SEC document |
| June 24, 2025 Filed Jun 27, 2025 10:00 UTC |
Neuman JohnDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 40,000 | $0.36 | $14,396.00 |
DisclosureSEC source: 0001213900-25-058569 · marketforms-69984.xml · nonDerivative · entry 1 Neuman John · CIK 0002026279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 F1 · price: The price reported in Column 4 is a weighted average price of $0.3599. These shares were purchased in multiple transactions at prices ranging from $0.359 to $0.36, inclusive. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 04, 2025 Filed Jul 2, 2025 23:32 UTC |
Baird Jennifer ADirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061153 · marketforms-70005.xml · derivative · entry 3 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F5 · derivative.exercise_date: As previously reported, on November 13, 2024, the reporting person was granted 8,000 RSUs, vesting in three approximately equal annual installments on the first, second and third anniversaries of June 4, 2024. F5 · derivative.expiration_date: As previously reported, on November 13, 2024, the reporting person was granted 8,000 RSUs, vesting in three approximately equal annual installments on the first, second and third anniversaries of June 4, 2024. F6 · balance_after: The total does not include 5,333 shares underlying RSUs that are now reported in Table I. Read SEC document |
| June 04, 2025 Filed Jul 2, 2025 23:32 UTC |
Baird Jennifer ADirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-061153 · marketforms-70005.xml · nonDerivative · entry 1 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 is being filed to report the vesting of certain restricted stock unit ("RSU") awards, the moving of unvested RSU awards previously reported in Table II to Table I and the open market purchase of shares of Common Stock. F2 · shares: Reflects RSUs that upon vesting converted into shares of ICU common stock. F3 · balance_after: The total includes 5,333 shares underlying RSUs that were previously reported in Table II. Read SEC document |
| June 04, 2025 Filed Jul 16, 2025 23:45 UTC |
Vincent Bernadette NDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064804 · marketforms-70102.xml · derivative · entry 3 Vincent Bernadette N · CIK 0002047074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F6 · derivative.exercise_date: As previously reported, on November 13, 2024, the reporting person was granted 8,000 RSUs, vesting in three approximately equal annual installments on the first, second and third anniversaries of June 4, 2024. F6 · derivative.expiration_date: As previously reported, on November 13, 2024, the reporting person was granted 8,000 RSUs, vesting in three approximately equal annual installments on the first, second and third anniversaries of June 4, 2024. F7 · balance_after: The total does not include 5,333 shares underlying RSUs that are now reported in Table I. Read SEC document |
| June 04, 2025 Filed Jul 16, 2025 23:45 UTC |
Vincent Bernadette NDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064804 · marketforms-70102.xml · nonDerivative · entry 1 Vincent Bernadette N · CIK 0002047074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 is being filed to report the granting and vesting of certain restricted stock unit ("RSU") awards and the moving of unvested RSU awards previously reported in Table II to Table I. F2 · shares: Reflects RSUs that upon vesting converted into shares of ICU common stock. F3 · balance_after: The total includes 5,333 shares underlying RSUs that were previously reported in Table II. Read SEC document |
| June 04, 2025 Filed Jul 16, 2025 23:45 UTC |
Neuman JohnDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064805 · marketforms-70099.xml · derivative · entry 3 Neuman John · CIK 0002026279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F6 · derivative.exercise_date: As previously reported, on November 13, 2024, the reporting person was granted 8,000 RSUs, vesting in three approximately equal annual installments on the first, second and third anniversaries of June 4, 2024. F6 · derivative.expiration_date: As previously reported, on November 13, 2024, the reporting person was granted 8,000 RSUs, vesting in three approximately equal annual installments on the first, second and third anniversaries of June 4, 2024. F7 · balance_after: The total does not include 5,333 shares underlying RSUs that are now reported in Table I. Read SEC document |
| June 04, 2025 Filed Jul 16, 2025 23:45 UTC |
Neuman JohnDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064805 · marketforms-70099.xml · nonDerivative · entry 1 Neuman John · CIK 0002026279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 is being filed to report the granting and vesting of certain restricted stock unit ("RSU") awards and the moving of unvested RSU awards previously reported in Table II to Table I. F2 · shares: Reflects RSUs that upon vesting converted into shares of ICU common stock. F3 · balance_after: The total includes 5,333 shares underlying RSUs that were previously reported in Table II. Read SEC document |
| June 04, 2025 Filed Jul 16, 2025 23:45 UTC |
Van Heel KennethDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064802 · marketforms-70100.xml · derivative · entry 3 Van Heel Kenneth · CIK 0001613111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 per share · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F6 · derivative.exercise_date: As previously reported, on November 13, 2024, the reporting person was granted 4,000 RSUs, which vested in full on June 4, 2025. F6 · derivative.expiration_date: As previously reported, on November 13, 2024, the reporting person was granted 4,000 RSUs, which vested in full on June 4, 2025. Read SEC document |
| June 04, 2025 Filed Jul 16, 2025 23:45 UTC |
Van Heel KennethDirector
|
Exercise / conversionCommon Stock, par value $0.0001 per share | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-064802 · marketforms-70100.xml · nonDerivative · entry 1 Van Heel Kenneth · CIK 0001613111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This Form 4 is being filed to report the granting and vesting of certain restricted stock unit ("RSU") awards. F2 · shares: Reflects RSUs that upon vesting converted into shares of ICU common stock. F3 · balance_after: On June 7, 2024, the Issuer effectuated a 1-for-25 reverse split of the Issuer's common stock resulting in a reduction in the number of shares held by the Reporting Person. In addition, proportionate adjustments were made to the Issuer's outstanding equity awards. Accordingly, all amounts of securities reported in this Form 4 have been adjusted to reflect the 1-for-25 reverse split. Read SEC document |
| May 20, 2025 Filed May 20, 2025 23:07 UTC |
Chung KevinChief Medical Officer
|
PurchaseCommon Stock, par value $0.0001 per share | 4,500 | $1.25 | $5,625.00 |
DisclosureSEC source: 0001213900-25-046119 · marketforms-69563.xml · nonDerivative · entry 1 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,185 Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:40 UTC |
Baird Jennifer ADirector
|
PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $1.28 | $12,815.00 |
DisclosureSEC source: 0001213900-25-046931 · marketforms-69582.xml · nonDerivative · entry 1 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price of $1.2815. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.29, inclusive. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 23:33 UTC |
Chung KevinChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-028748 · marketforms-69091.xml · derivative · entry 1 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, par value $0.0001 per share · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2 · derivative.exercise_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of April 1, 2025. F2 · derivative.expiration_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of April 1, 2025. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 23:33 UTC |
Green David AChief Financial Officer
|
GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-028747 · marketforms-69089.xml · derivative · entry 1 Green David A · CIK 0001372822 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, par value $0.0001 per share · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2 · derivative.exercise_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of April 1, 2025. F2 · derivative.expiration_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of April 1, 2025. Read SEC document |
| December 11, 2024 Filed Feb 27, 2025 20:51 UTC |
Neuman JohnDirector
|
PurchaseCommon Stock, par value $0.0001 per share | 10,000 | $2.04 | $20,405.00 |
DisclosureSEC source: 0001213900-25-017946 · marketforms-68494.xml · nonDerivative · entry 4 Neuman John · CIK 0002026279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F4 · price: 4. The price reported in Column 4 is a weighted average price of $2.0405. These shares were purchased in multiple transactions at prices ranging from $2.01 to $2.06, inclusive. The reporting person undertakes to provide, upon request by the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 18, 2024 Filed Nov 19, 2024 22:18 UTC |
Chung KevinChief Medical Officer
|
PurchaseCommon Stock, par value $0.0001 per share | 4,250 | $1.99 | $8,457.50 |
DisclosureSEC source: 0001213900-24-100248 · marketforms-67373.xml · nonDerivative · entry 1 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,685 Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:18 UTC |
Schlorff EricDirector · Chief Executive Officer
|
GrantRestricted Stock Unit · Derivative | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-100246 · marketforms-67374.xml · derivative · entry 1 Schlorff Eric · CIK 0001949738 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock, par value $0.0001 per share · 65,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2 · derivative.exercise_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of July 1, 2024. F2 · derivative.expiration_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of July 1, 2024. Read SEC document |
| November 15, 2024 Filed Nov 19, 2024 22:18 UTC |
Chung KevinChief Medical Officer
|
GrantRestricted Stock Unit · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-100248 · marketforms-67373.xml · derivative · entry 2 Chung Kevin · CIK 0001949950 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, par value $0.0001 per share · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2 · derivative.exercise_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of July 1, 2024. F2 · derivative.expiration_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of July 1, 2024. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:37 UTC |
Neuman JohnDirector
|
GrantRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-099147 · marketforms-67356.xml · derivative · entry 1 Neuman John · CIK 0002026279 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock, par value $0.0001 per share · 8,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2 · derivative.exercise_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of June 4, 2024 F2 · derivative.expiration_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of June 4, 2024 Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 16:38 UTC |
Barnett RickDirector
|
GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-099150 · marketforms-67351.xml · derivative · entry 1 Barnett Rick · CIK 0001949746 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock, par value $0.0001 per share · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock F2 · derivative.exercise_date: 100% of the restricted stock units vest on June 4, 2025. F2 · derivative.expiration_date: 100% of the restricted stock units vest on June 4, 2025. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:37 UTC |
Van Heel KennethDirector
|
GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-099149 · marketforms-67355.xml · derivative · entry 1 Van Heel Kenneth · CIK 0001613111 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock, par value $0.0001 per share · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2 · derivative.exercise_date: 100% of the restricted stock units vest on June 4, 2025. F2 · derivative.expiration_date: 100% of the restricted stock units vest on June 4, 2025. Read SEC document |
| November 13, 2024 Filed Nov 15, 2024 21:36 UTC |
Collins AllanDirector
|
GrantRestricted Stock Unit · Derivative | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-099146 · marketforms-67352.xml · derivative · entry 1 Collins Allan · CIK 0001950453 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock, par value $0.0001 per share · 4,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock F2 · derivative.exercise_date: 100% of the restricted stock units vest on June 4, 2025. F2 · derivative.expiration_date: 100% of the restricted stock units vest on June 4, 2025. Read SEC document |
| November 13, 2024 Filed Dec 4, 2024 02:40 UTC |
Baird Jennifer ADirector
|
GrantRestricted Stock Unit · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-105215 · marketforms-67361.xml · derivative · entry 1 Baird Jennifer A · CIK 0002047015 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock, par value $0.0001 per share · 8,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ICU common stock. F2 · derivative.exercise_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of June 4, 2024 F2 · derivative.expiration_date: The RSUs reported herein will vest in equal installments on the first, second and third anniversaries of June 4, 2024 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.